TFFP Insider Trading

Insider Ownership Percentage: 4.50%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00

TFF Pharmaceuticals Insider Trading History Chart

This chart shows the insider buying and selling history at TFF Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$4M-$2M$0$2M$4MTotal Insider BuyingTotal Insider Selling

TFF Pharmaceuticals Share Price & Price History

Current Price: $0.07
Price Change: +0.30 (1.20%)
As of 04/2/2025 01:00 AM ET

This chart shows the closing price history over time for TFFP up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
MayJunJulAugSepOctNovDecJanFebMar$0.07Closing price on 04/03/25:

SEC Filings (Institutional Ownership Changes) for TFF Pharmaceuticals (NASDAQ:TFFP)

15.25% of TFF Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at TFFP by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$100k$0$100kTotal InflowsTotal Outflows
TFF Pharmaceuticals logo
TFF Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company's drug candidates are TFF Voriconazole Inhalation Powder, which is in Phase II clinical trials for the treatment and prophylaxis of invasive pulmonary aspergillosis; and TFF Tacrolimus Inhalation Powder, which is in Phase II clinical trials used to prevent lung transplant rejection. It also develops other dry powder products, such as Augmenta human derived monoclonal antibodies for the treatment of COVID-19 disease; and other vaccines. It has a license agreement with the University of Texas at Austin for the development of inhaled dry powder drugs. TFF Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Fort Worth, Texas.
Read More on TFF Pharmaceuticals

Today's Range

Now: $0.07
Low: $0.07
High: $0.07

50 Day Range

MA: $0.06
Low: $0.07
High: $0.07

52 Week Range

Now: $0.07
Low: $0.06
High: $5.27

Volume

N/A

Average Volume

619,020 shs

Market Capitalization

$288,795.00

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.07

Who are the company insiders with the largest holdings of TFF Pharmaceuticals?

TFF Pharmaceuticals' top insider shareholders include:
  1. Carlson Capital L P (Major Shareholder)
  2. Harlan F Weisman (CEO)
  3. Zamaneh Mikhak (Insider)
  4. Stephen Rocamboli (Director)
Learn More about top insider investors at TFF Pharmaceuticals.